Next-generation molecular therapy in lung cancer

The identification of molecular subsets of non-small cell lung cancer (NSCLC) has completely modified our approach to the management of this disease. NSCLC is the most common type of lung cancer (80–85%), which is the number one cancer killer in the nation and worldwide (1). NSCLC can be further pathologically divided into two main subtypes including adenocarcinoma (ADC, 40%) and squamous cell carcinoma (SCC, 25%).